Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
AIDS (London, England)|February 24, 2001
Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapyM Jouan, M Savès, R Tubiana, et al.
AIDS Care|November 30, 2006
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patientsC R Fumaz, J A Muñoz-Moreno, A L Ballesteros, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 15, 2000
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapyA Tuldrà, C R Fumaz, M J Ferrer, et al.
Sexually Transmitted Infections|November 7, 2008
Recently acquired HIV infection in Spain (2003-2005): introduction of the serological testing algorithm for recent HIV seroconversionA Romero, V González, M Granell, et al.
The Journal of Antimicrobial Chemotherapy|April 14, 2009
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patientsJ Berenguer, J González-García, J López-Aldeguer, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 13, 2012
Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS CohortC Manzardo, A Esteve, N Ortega, et al.
The Journal of Infection|June 24, 2008
HIV-1 infected patients older than 50 years. PISCIS cohort studyG Navarro, M M Nogueras, F Segura, et al.
Antiviral Therapy|July 19, 2005
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-upE Negredo, R Paredes, A Bonjoch, et al.
HIV Medicine|August 9, 2011
The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysisM Murray, R S Hogg, V D Lima, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2016
HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllersB Dominguez-Molina, L Tarancon-Diez, S Hua, et al.
Pageof 5